Yan, Yu
Liu, Hongbo http://orcid.org/0000-0002-0733-8616
Abedini, Amin http://orcid.org/0000-0002-8875-0070
Sheng, Xin http://orcid.org/0000-0002-3620-3577
Palmer, Matthew
Li, Hongzhe
Susztak, Katalin http://orcid.org/0000-0002-1005-3726
Article History
Received: 11 June 2023
Accepted: 19 January 2024
First Online: 29 January 2024
Change Date: 21 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-46661-6
Competing interests
: K. Susztak declares the following interests: research support from AstraZeneca, Bayer, Boehringer Ingelheim, Calico, Genentech, Gilead, GSK, Jnana, Lilly, Maze, Merck, Novartis, Novo Nordisk, Regeneron, Variant Bio, and Ventus; advisory board membership with Jnana Therapeutics and Pfizer; consultancy for AstraZeneca, Bayer, GSK, Jnana Therapeutics, Maze, Novo Nordisk, Pfizer, and Ventus; ownership of patents related to Jag1- and Notch-based targeting of chronic kidney disease; editorial board membership with <i>Cell Metabolism</i>, <i>eBioMedicine</i>, <i>Journal of the American Society of Nephrology</i>, <i>Journal of Clinical Investigation</i>, <i>Kidney International</i>, and <i>Med</i>. The remaining authors declare no competing interests.